<div id="readability-page-1"><div> <div> , /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (&#34;ADMA&#34; or the &#34;Company&#34;) (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether ADMA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On March 24, 2026, Culper Research published a short report on ADMA, alleging that &#34;ADMA's reported growth is a fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor&#34; and &#34;estimat[ing] that, absent channel stuffing, ADMA revenues declined 3% in 2025 vs. +20% reported.&#34; Following publication of the Culper report, ADMA's stock price fell $2.26 per share, or 16.63%, to close at $11.33 per share on March 24, 2026. Then, on March 26, 2026, Cantor Fitzgerald downgraded ADMA, citing disappointment with the Company's response to the Culper report, which Cantor Fitzgerald found lacking in &#34;specific feedback addressing the direct claims in the report.&#34; Following the downgrade, ADMA's stock price fell $1.34 per share, or 13.91%, to close at $8.29 per share on March 26, 2026. Then, on May 6, 2026, ADMA withdrew its long-term financial guidance, citing evolving U.S. plasma products and immunoglobulin market competitive dynamics. On this news, ADMA's stock price fell $1.61 per share, or 15.97%, to close at $8.47 per share on May 7, 2026. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9REM2MDU0MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQyMDE1UFJfTkVXU19VU1BSX19fX19EQzYwNTQz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9REM2MDU0MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQyMDE1UFJfTkVXU19VU1BSX19fX19EQzYwNTQz"/></div> </div></div>

ADMA

Pomerantz Law Firm is investigating claims on behalf of investors of ADMA Biologics, Inc. regarding potential securities fraud and unlawful business practices. Following a critical report by Culper Research, ADMA's stock price experienced significant declines, leading to a downgrade by Cantor Fitzgerald. The firm is encouraging affected investors to contact them for more information about joining a class action.

prnewswire

Adma Biologics

VG Health

Health Care Select Sector SPDR

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Ark Genomic Revolution ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

20:15 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA